Metabolic Weekly

Research

In-depth analysis of the latest clinical trials, studies, and scientific research on GLP-1 medications.

Research

Unlocking GLP-1 Variability: Why Weight Loss Differs So Wildly

GLP-1 receptor agonists have revolutionized weight management, offering unprecedented results for many, yet a significant proportion of patients experience only modest benefit. While some individuals achieve remarkable 25% body weight reductions, others see just 5% loss, prompting crucial research into this variability and the factors at play. This article explores the complex interplay of genetic predispositions, metabolic profiles, and lifestyle factors that dictate these divergent outcomes, providing essential insights for optimizing GLP-1 therapy and understanding personalized responses to achieve your weight loss goals.

Priya Mehra Priya Mehra · 7 min read
Research

The Surprising Link: Autophagy, Fasting, and GLP-1s for Weight Loss

Globally, obesity rates are soaring, prompting a critical search for effective weight management strategies beyond traditional diets. This article delves into the fascinating intersection of autophagy, the body's cellular recycling process, and its profound role in weight loss, exploring how both intermittent fasting and revolutionary GLP-1 medications like Ozempic and Wegovy leverage remarkably similar biological pathways to promote metabolic health. Discover the shared mechanisms behind these powerful, modern approaches and how understanding their common ground can offer new, sustainable perspectives on combating the global obesity crisis.

Priya Mehra Priya Mehra · 7 min read
Research

Semaglutide Shows Promise for Adolescent Obesity: Unpacking STEP TEENS

Obesity in adolescents is a growing public health concern, with significant long-term health implications. The groundbreaking STEP TEENS trial investigated the efficacy and safety of semaglutide in this vulnerable population, offering new hope for effective treatment strategies. This article delves into the key findings and implications of the STEP TEENS data, exploring how semaglutide could transform the landscape of adolescent obesity management and improve health outcomes for millions.

Priya Mehra Priya Mehra · 7 min read
Research

Can Lab Tests Predict Your GLP-1 Response? Unpacking Gut Peptide Science

As GLP-1 agonists revolutionize metabolic health, a critical question emerges: can we predict individual responses before treatment begins? This article delves into the cutting-edge science of gut peptide testing, exploring whether specific lab markers can offer insights into how effectively your body might respond to GLP-1 therapies. Discover the potential for personalized medicine in obesity and diabetes management, and what current research suggests about optimizing treatment strategies through advanced diagnostics.

Priya Mehra Priya Mehra · 7 min read
Research

Semaglutide and Blood Clot Risk: Evaluating the Safety Signal

Semaglutide has become a cornerstone in Type 2 diabetes management, but recent safety signals linking it to an increased risk of blood clots demand thorough investigation. With millions relying on such medications, understanding these potential adverse effects is paramount for patient safety. This article critically examines the current scientific evidence, evaluating the data to provide clarity on these risks and their implications for treatment protocols. Stay informed on what these findings mean for you or your loved ones managing diabetes, empowering you with crucial information.

Priya Mehra Priya Mehra · 7 min read
Research

GLP-1s & Gender: Are Weight Loss Results Different for Men & Women?

Emerging research suggests a significant disparity in how GLP-1 receptor agonists impact weight loss between men and women. While both genders benefit, women consistently achieve greater absolute and relative weight reduction, a trend highlighted by a recent meta-analysis of nearly 20,000 participants. This raises crucial questions about underlying physiological differences, hormonal influences, and treatment optimization strategies. Dive into the latest findings to understand why GLP-1 drugs might work differently across genders and what this means for personalized metabolic health.

Priya Mehra Priya Mehra · 7 min read
Research

GLP-1s for Seniors: Unpacking Efficacy, Safety, and Unique Considerations

With obesity rates soaring among US adults aged 60 and older, the demand for effective weight management solutions is more urgent than ever. GLP-1 receptor agonists have revolutionized treatment for type 2 diabetes and obesity, but their application in older populations presents unique challenges and opportunities. This article delves into the specific efficacy, safety profiles, and critical considerations for prescribing GLP-1 drugs to seniors, exploring how these powerful medications can be optimally integrated into care plans while mitigating potential risks and maximizing benefits for this vulnerable demographic.

Priya Mehra Priya Mehra · 7 min read
Research

Beyond GLP-1: GIP's Crucial Role in Tirzepatide's Weight Loss Success

The landscape of metabolic disease treatment is undergoing a profound transformation, spearheaded by therapies that leverage the body’s innate hormonal systems. Among these, tirzepatide stands out as a groundbreaking medication, not just for its efficacy but for its unique dual mechanism targeting both GLP-1 and GIP receptors. This article delves into the often-underestimated role of Glucose-dependent Insulinotropic Polypeptide (GIP) in weight loss, explaining how its synergistic action with GLP-1 contributes to tirzepatide's remarkable success in managing obesity and type 2 diabetes. Discover why understanding GIP is key to appreciating the next generation of metabolic therapies.

Priya Mehra Priya Mehra · 7 min read
Research

Navigating GLP-1s: Assessing Gastroparesis Risk & Management Strategies

GLP-1 receptor agonists have revolutionized diabetes and weight management, yet concerns regarding their potential to exacerbate or induce gastroparesis are growing. With gastroparesis affecting a significant portion of individuals with diabetes—up to 50% in type 1 and 15% in type 2—understanding this complex interaction is crucial for clinicians and patients alike. This article delves into the latest research on GLP-1 drugs and their link to gastroparesis, offering a comprehensive risk assessment framework and practical management strategies to ensure optimal patient outcomes while leveraging the benefits of these powerful medications.

Priya Mehra Priya Mehra · 7 min read
Research

Unlocking GLP-1 Mysteries: Why Patient Responses Differ So Widely

GLP-1 receptor agonists have revolutionized metabolic health, yet their efficacy varies significantly among patients. While some experience dramatic improvements in obesity and type 2 diabetes, others achieve more modest results. This article explores the intricate genetic, environmental, and physiological factors driving these individual differences, highlighting the latest research aimed at personalizing GLP-1 therapies and optimizing patient outcomes.

Priya Mehra Priya Mehra · 7 min read
Research

Semaglutide's Game-Changing Role in HFpEF: The STEP-HFpEF Trial Unveiled

The landscape of heart failure with preserved ejection fraction (HFpEF) is undergoing a significant transformation thanks to groundbreaking research. The STEP-HFpEF trial has delivered remarkable results, showcasing semaglutide's potential to dramatically improve symptoms, physical limitations, and quality of life for patients battling this debilitating condition. This breakthrough offers a beacon of hope, addressing a critical unmet need in cardiovascular medicine and paving the way for new therapeutic strategies that could redefine patient care.

Priya Mehra Priya Mehra · 7 min read
Research

AI Revolutionizes Metabolic Drug Discovery: A New Era for Treatment

The global metabolic crisis demands innovative solutions, and artificial intelligence is emerging as a powerful catalyst in the race for new drug discoveries. This article explores how cutting-edge AI algorithms are rapidly transforming every stage of drug development, from identifying novel therapeutic targets and screening vast chemical libraries to optimizing compound design and predicting clinical outcomes with remarkable accuracy. Discover the groundbreaking ways AI is accelerating the pipeline for metabolic medicines, offering unprecedented hope for millions grappling with conditions like obesity and diabetes, and paving the way for more effective, personalized treatments that could redefine patient care.

Priya Mehra Priya Mehra · 7 min read
Research

GLP-1 Drugs and Bone Health: Unpacking the Fracture Risk Debate

As GLP-1 receptor agonists become increasingly popular for weight management, a critical question emerges: do these powerful medications impact bone health and potentially increase fracture risk? With obesity rates soaring, understanding the full spectrum of GLP-1 effects, including their influence on skeletal integrity, is paramount for both patients and clinicians. This article delves into the latest research, exploring the complex interplay between GLP-1 drugs, weight loss, and bone density to provide clarity on this evolving area of metabolic health.

Priya Mehra Priya Mehra · 7 min read
Research

The Obesity Paradox: Unpacking Why Higher BMI Can Seem Protective

The concept of the 'obesity paradox' suggests that in certain conditions, individuals with a higher BMI might experience better health outcomes or survival rates, seemingly contradicting the widely accepted health risks associated with obesity. This intriguing phenomenon has sparked considerable debate and research, prompting a closer look at the nuances of BMI, metabolic health, and disease progression. We delve into the complexities behind this apparent protection, exploring the specific contexts where it appears, and critically examining why this 'paradox' can be deeply misleading for public health understanding and individual health decisions.

Priya Mehra Priya Mehra · 7 min read
Research

GLP-1 Drugs: A New Path to Reducing Inflammation Beyond Weight Loss

Chronic low-grade inflammation, a silent epidemic underlying metabolic dysfunction, affects an estimated 70% of individuals with obesity. While GLP-1 receptor agonists are widely celebrated for their profound weight loss benefits, groundbreaking new research indicates these powerful drugs may also directly combat inflammation through mechanisms independent of weight reduction. This article explores the latest scientific discoveries, revealing how GLP-1 drugs exert their anti-inflammatory effects and offering a deeper understanding of their potential to revolutionize treatment approaches for a broader spectrum of metabolic health conditions.

Priya Mehra Priya Mehra · 7 min read
Research

Bimagrumab & Semaglutide: A Breakthrough for Muscle-Sparing Weight Loss

America's obesity crisis demands innovative solutions that go beyond simple weight reduction. While powerful new anti-obesity medications offer unprecedented weight loss, a critical challenge remains: preserving lean muscle mass. Emerging research suggests a groundbreaking combination of bimagrumab and semaglutide could revolutionize treatment, offering significant fat loss while actively protecting and even building muscle. This dual-action approach promises a healthier, more sustainable path to managing obesity and improving metabolic health.

Priya Mehra Priya Mehra · 7 min read
Research

Unlocking GLP-1's Reach: How Receptor Distribution Drives Widespread Drug Effects

GLP-1 receptor agonists have revolutionized metabolic health, but their impact extends far beyond blood sugar control. This article delves into the intricate distribution of GLP-1 receptors throughout the human body, revealing why these powerful medications influence a diverse array of physiological systems, from the brain to the gut. Understanding this widespread presence is key to appreciating both the therapeutic potential and the multifaceted side effects of these groundbreaking drugs, offering new insights into their broad systemic influence.

Priya Mehra Priya Mehra · 7 min read
Research

OASIS Trials Unveil Game-Changing High-Dose Oral Semaglutide Results

The landscape of obesity treatment is undergoing a seismic shift, with recent data from the OASIS trials heralding a new era of oral options. Specifically, the OASIS 4 trial showcased that once-daily high-dose oral semaglutide demonstrated significant weight loss and improved metabolic markers, offering a convenient and effective alternative to injectables. This breakthrough could revolutionize patient access and adherence, making advanced obesity management more accessible than ever before. Discover how these pivotal findings are set to reshape clinical practice and patient outcomes.

Priya Mehra Priya Mehra · 7 min read
Research

GLP-1 Drugs and Fertility: Essential Insights for Men and Women Before Starting

GLP-1 receptor agonists are transforming metabolic health, but their impact on reproductive science, particularly fertility for both men and women, is a critical area of ongoing research. As more individuals consider these powerful medications, understanding the potential implications for family planning and reproductive health becomes paramount. This article delves into the latest findings, offering crucial insights and considerations for anyone contemplating GLP-1 therapy while planning for a family, ensuring informed decisions in this rapidly evolving landscape.

Priya Mehra Priya Mehra · 7 min read
Research

Beyond GLP-1: How Dual & Triple Agonists Revolutionize Metabolic Health

The landscape of metabolic medicine is undergoing a profound transformation, driven by an understanding of complex hormonal interplay. With 42.4% of U.S. adults grappling with obesity, the search for more effective treatments is urgent. This article delves into the groundbreaking potential of dual and triple agonists, exploring how targeting multiple receptors simultaneously could offer superior outcomes compared to single-target therapies. Discover the science behind these innovative compounds and why a multi-faceted approach might be the key to unlocking better metabolic health and weight management for millions.

Priya Mehra Priya Mehra · 7 min read
Research

GLP-1s & Pancreatitis: Unpacking Real vs. Theoretical Risk

The association between GLP-1 receptor agonists and acute pancreatitis has been a persistent point of discussion in metabolic health circles. While rare, this severe inflammation of the pancreas warrants careful consideration for patients and clinicians alike. This article delves into the latest research, aiming to distinguish between substantiated risks and theoretical concerns, providing clarity on the safety profile of these transformative diabetes and weight-loss medications. Understanding the nuances is crucial for informed treatment decisions and patient reassurance.

Priya Mehra Priya Mehra · 7 min read
Research

Decoding Semaglutide: A Deep Dive into the Transformative STEP Trials

The global health crisis of obesity continues to escalate, with over 42% of US adults affected, highlighting an urgent need for effective interventions. Semaglutide has emerged as a significant player in this fight, but its impact extends far beyond simple weight management. This article delves into the comprehensive STEP (Semaglutide Treatment Effect in People with Obesity) trials, revealing the full spectrum of conditions and outcomes semaglutide has been rigorously tested for, from cardiovascular benefits to long-term metabolic health improvements. Discover how these pivotal studies are reshaping our understanding of obesity treatment and the broader implications for patient care.

Priya Mehra Priya Mehra · 7 min read
Research

GLP-1s & Cancer Risk: Unpacking the Latest Research & Patient Safety

With GLP-1 receptor agonist prescriptions skyrocketing, a critical question for patients and clinicians alike is the potential link between these popular medications and cancer risk. Emerging data offers complex insights, prompting a deeper dive into ongoing studies and real-world evidence. This article explores the current scientific consensus, examines conflicting findings, and provides a balanced perspective on what the latest research indicates about GLP-1s and long-term safety, helping you understand the nuances of this evolving medical landscape.

Priya Mehra Priya Mehra · 7 min read
Research

Can GLP-1 Drugs Prevent Weight Regain After Bariatric Surgery?

Up to 30% of bariatric surgery patients regain significant weight within five years—a frustrating reality that has prompted researchers to investigate whether GLP-1 receptor agonists like semaglutide and tirzepatide can help maintain surgical weight loss. New clinical studies suggest these medications may offer a powerful tool for post-surgical weight management, potentially transforming long-term outcomes for patients who've undergone gastric bypass or sleeve gastrectomy. This emerging research explores the mechanisms, efficacy, and practical considerations of combining metabolic surgery with pharmaceutical intervention.

Priya Mehra Priya Mehra · 7 min read
Research

SURMOUNT-1: Inside the Largest Weight Loss Drug Trial in History

The SURMOUNT-1 trial enrolled over 2,500 participants to test tirzepatide for weight loss, making it the largest study of its kind ever conducted. Results showed participants on the 15 mg dose lost an average of 20.9% of their body weight over 72 weeks—nearly a quarter of their starting weight. Beyond the headline numbers, the trial revealed crucial insights about who responds best, what side effects to expect, and how this dual GIP/GLP-1 medication compares to existing treatments. Here's what the data actually shows.

Priya Mehra Priya Mehra · 7 min read
Research

GLP-1 Drugs During Perimenopause: What Women Need to Know

As 42% of women gain 10+ pounds during menopause, GLP-1 medications like Ozempic and Wegovy are emerging as potential tools for managing perimenopausal weight gain. But how do these drugs interact with fluctuating hormones, and what does the latest research reveal about their safety and effectiveness during this transitional phase? Here's what the science says about using GLP-1 receptor agonists when your body is already undergoing significant metabolic changes.

Priya Mehra Priya Mehra · 7 min read
Research

The Microbiome-Obesity Connection: What GLP-1 Drugs Do to Gut Bacteria

While 42.4% of U.S. adults struggle with obesity, emerging research reveals that GLP-1 medications like semaglutide and tirzepatide don't just suppress appetite—they fundamentally reshape the trillions of bacteria living in your gut. New studies show these drugs alter microbial composition in ways that may explain their effectiveness beyond weight loss, including improvements in inflammation and metabolic health. Understanding this gut-brain-metabolism axis could unlock why some patients respond better than others.

Priya Mehra Priya Mehra · 7 min read
Research

GLP-1 Drugs and Exercise: What Research Shows About Muscle Loss

New research reveals that 63% of semaglutide patients experience significant muscle loss alongside fat reduction when exercise isn't integrated into their treatment plan. While GLP-1 medications deliver impressive weight loss results, emerging data from clinical trials suggests that combining these drugs with structured physical activity is essential for preserving lean muscle mass and optimizing metabolic outcomes. Understanding how to pair GLP-1 therapy with the right exercise protocol could be the difference between losing weight and losing health.

Priya Mehra Priya Mehra · 7 min read
Research

HRT and GLP-1s Together: 24.6% Weight Loss in New Study

Women combining tirzepatide with hormone replacement therapy achieved 24.6% body weight loss at 72 weeks—significantly more than the 18.2% lost with GLP-1 medication alone. This emerging research suggests that HRT may enhance metabolic medication efficacy in perimenopausal and postmenopausal women, addressing a critical gap in weight management approaches. The findings raise important questions about optimizing treatment protocols for women navigating hormonal transitions.

Priya Mehra Priya Mehra · 7 min read
Research

Semaglutide Shows Promise Against Alzheimer's in Early Studies

As GLP-1 receptor agonists like semaglutide become increasingly prescribed for metabolic conditions, researchers are uncovering unexpected neuroprotective benefits. With over 42% of US adults aged 60+ living with prediabetes, the intersection of metabolic dysfunction and cognitive decline has never been more relevant. Early clinical evidence suggests semaglutide may reduce Alzheimer's risk and slow neurodegeneration through mechanisms beyond glucose control. This article examines the emerging research connecting metabolic health, GLP-1 medications, and brain protection.

Priya Mehra Priya Mehra · 7 min read
Research

GLP-1 Drugs Cut Addiction Risk by Half: The Smoking-to-Gambling Link

A landmark study of 603,000 type 2 diabetes patients reveals that GLP-1 receptor agonists reduce addiction-related behaviors by 50-56%, spanning everything from smoking cessation to reduced gambling urges. The findings suggest these metabolic medications may be rewiring reward pathways in the brain, opening unexpected therapeutic possibilities beyond diabetes and weight loss. Researchers are now investigating whether drugs like semaglutide and tirzepatide could become legitimate treatments for substance use disorders and behavioral addictions.

Priya Mehra Priya Mehra · 7 min read
Research

Ozempic Is Quietly Reducing Alcohol Cravings and Addiction — Here Is the Science

Patients on GLP-1 drugs like Ozempic and Wegovy are reporting dramatic reductions in alcohol cravings and addictive behaviors. Here is the research behind the surprising brain effect that is driving this.

Finn Reardon Finn Reardon · 8 min read
Research

GLP-1 Drugs Show Unexpected Kidney Protection Beyond Diabetes Control

New research reveals GLP-1 receptor agonists may protect kidney function in ways that extend far beyond glucose management. With 37 million Americans living with chronic kidney disease—many undiagnosed—and diabetes patients facing a 38% risk of kidney complications, these findings represent a potential paradigm shift in nephroprotection. Clinical trials demonstrate significant reductions in kidney disease progression, even in patients without diabetes, suggesting these medications may become a cornerstone of kidney disease prevention and treatment strategies.

Priya Mehra Priya Mehra · 7 min read
Research

GLP-1 Drugs for Kids: What Pediatric Obesity Trials Really Show

With nearly 20% of US children affected by obesity, pediatric trials of GLP-1 medications like liraglutide and semaglutide are revealing promising but complex results. Recent studies show significant weight reduction in adolescents, but questions remain about long-term safety, appropriate age ranges, and psychological impacts. As the FDA expands approvals for younger patients, clinicians and parents face difficult decisions about when—and whether—metabolic interventions are appropriate for developing bodies.

Priya Mehra Priya Mehra · 7 min read
Research

Fewer GLP-1 Shots May Be Enough to Maintain Weight Loss for Some Patients, Study Finds

A new review found that a subset of patients maintained weight loss after reducing GLP-1 injection frequency from weekly to biweekly or monthly. Here is what the data shows and who it applies to.

Maren Thiessen Maren Thiessen · 8 min read
Research

GLP-1 Drugs Like Ozempic May Help the Heart Recover After a Heart Attack, New Study Finds

A study from Bristol and UCL published in Nature Communications found GLP-1 drugs may prevent a serious complication called no-reflow that affects nearly half of heart attack patients — and the benefit appears independent of weight loss.

Wyatt Okonkwo Wyatt Okonkwo · 7 min read
Research

Bariatric Surgery Beats GLP-1 Drugs 5-to-1 for Weight Loss — Here Is What That Headline Is Missing

A real-world study found bariatric surgery produces five times more weight loss than Ozempic and Zepbound. Here is the full picture: who surgery is actually right for, and why most people reading this should still consider GLP-1 medications first.

Brock Halverson Brock Halverson · 9 min read
Research

GLP-1 Drugs and Seasonal Weight Gain: What the Research Actually Shows

Do GLP-1 medications like Ozempic and Zepbound protect against seasonal weight gain? Here is what two years of trial data says, and practical strategies to protect your progress year-round.

Maren Thiessen Maren Thiessen · 8 min read
Research

The Gut-Brain Axis: How GLP-1 Drugs Actually Suppress Appetite

GLP-1 receptor agonists don't just mimic a hormone—they hijack an ancient communication pathway between your gut and brain. Within days of starting treatment, 70% of patients experience dramatic appetite suppression, but the mechanism involves far more than simple satiety signaling. From vagal nerve stimulation to hypothalamic receptor binding, understanding how these medications work reveals why they're revolutionizing obesity treatment and why individual responses vary so widely.

Priya Mehra Priya Mehra · 7 min read
Research

GLP-1 Drugs Show Promise in Reversing Fatty Liver Disease

New clinical data reveals that GLP-1 receptor agonists may reverse metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NAFLD, in a significant portion of patients. With approximately 25% of adults worldwide affected by excess liver fat, these findings offer hope for addressing a condition that has long lacked effective pharmaceutical interventions. The research demonstrates measurable improvements in liver inflammation, fibrosis markers, and fat accumulation—outcomes that could transform treatment paradigms for metabolic liver disease.

Priya Mehra Priya Mehra · 7 min read
Research

PCOS and GLP-1 Drugs: What the Emerging Research Shows

Polycystic ovary syndrome affects millions of women worldwide, with up to 80% experiencing insulin resistance as a core metabolic dysfunction. As GLP-1 receptor agonists gain attention beyond diabetes and weight management, emerging research suggests these medications may address multiple aspects of PCOS—from hormonal imbalances to metabolic markers. This comprehensive review examines the latest clinical evidence on GLP-1 drugs for PCOS management and what women and healthcare providers should know about this evolving treatment landscape.

Priya Mehra Priya Mehra · 7 min read
Research

How GLP-1 Drugs Affect Mental Health: The Emerging Evidence

As millions of Americans take GLP-1 receptor agonists for weight loss, an unexpected pattern is emerging: significant effects on mental health. Patients report reduced anxiety, improved mood, and decreased addictive behaviors, while researchers scramble to understand the neurological mechanisms behind these psychiatric changes. This comprehensive analysis examines the latest clinical findings, patient experiences, and what the mental health implications mean for the 42.4% of US adults living with obesity who are considering or currently using these medications.

Priya Mehra Priya Mehra · 7 min read
Research

GLP-1 Drugs Show Promise for Sleep Apnea in SURMOUNT-OSA Trial

The SURMOUNT-OSA trial has revealed significant findings about tirzepatide's impact on obstructive sleep apnea, a condition affecting 39 million American adults. This groundbreaking research demonstrates how GLP-1 receptor agonists may offer a pharmacological treatment option for OSA patients, particularly those struggling with obesity-related sleep disorders. The study's results suggest a potential paradigm shift in managing sleep apnea beyond traditional CPAP therapy and surgical interventions.

Priya Mehra Priya Mehra · 7 min read
Research

Women Lose 57% More Weight Than Men on GLP-1 Drugs, Johns Hopkins Meta-Analysis Finds

A 64-trial JAMA Internal Medicine meta-analysis from Johns Hopkins Bloomberg School of Public Health found GLP-1 medications are equally effective across age, race, and BMI — but women lose about 11% of body weight versus 7% for men.

Delia Kimura Delia Kimura · 7 min read
Research

Ozempic Is Changing How People Feel Emotionally, Not Just Physically — What the Brain Research Shows

Patients report dramatic reductions in anxiety, depression, and addictive urges on GLP-1 medications. Researchers are now investigating whether semaglutide and tirzepatide directly affect brain reward circuitry — and what that means for mental health treatment.

Renata Solís Renata Solís · 8 min read
Research

SURMOUNT-4 Trial Reveals What Happens When You Stop Tirzepatide

The SURMOUNT-4 trial delivered a stark message about tirzepatide discontinuation: participants who stopped treatment regained 14% of their body weight within a year, while those who continued lost an additional 5.5%. This carefully designed withdrawal study illuminates not just the medication's efficacy, but fundamental questions about weight maintenance, metabolic adaptation, and what "long-term use" really means for the millions considering GLP-1 therapies. The data challenges assumptions about temporary treatment and raises important discussions about sustainability.

Priya Mehra Priya Mehra · 7 min read
Research

Weight Regain After Stopping GLP-1s: What Research Shows

Clinical trials reveal that two-thirds of weight lost on semaglutide returns within a year of discontinuation, raising critical questions about long-term treatment strategies. The STEP 4 trial and subsequent research demonstrate that GLP-1 receptor agonists require ongoing use to maintain benefits, challenging assumptions about short-term intervention. Understanding the metabolic mechanisms behind weight regain helps patients and providers make informed decisions about sustainable weight management approaches.

Priya Mehra Priya Mehra · 7 min read
Research

Both Ozempic and Zepbound Protect Your Heart — New Mass General Brigham Study Involving 1 Million Patients

A landmark real-world study from Mass General Brigham published in Nature Medicine found both semaglutide and tirzepatide significantly reduce the risk of heart attack, stroke, and death in patients with type 2 diabetes.

Wyatt Okonkwo Wyatt Okonkwo · 7 min read
Research

GLP-1 Drugs Are Changing How Patients Drink—Here's What We Know

Patients taking Ozempic and Wegovy are reporting an unexpected side effect: a sudden, dramatic decrease in their desire for alcohol. These aren't subtle changes—users describe losing interest in drinking almost overnight. As reports flood online forums and catch researchers' attention, scientists are racing to understand how these diabetes and weight-loss medications might be rewiring the brain's reward pathways. The implications could extend far beyond metabolic health, potentially opening new frontiers in addiction treatment.

Priya Mehra Priya Mehra · 7 min read
Research

Ozempic and Wegovy May Raise Osteoporosis and Gout Risk, New Research Warns

A large study of 146,000+ patients presented at AAOS 2026 found GLP-1 users had higher rates of osteoporosis and gout. Here's what the findings actually mean — and what they don't.

Maren Thiessen Maren Thiessen · 7 min read
Research

Ozempic May Repair Arthritic Joints — And Weight Loss Has Nothing to Do With It

A new study in Cell Metabolism found semaglutide reverses osteoarthritis tissue damage through a weight-loss-independent mechanism, reprogramming cartilage cells to regenerate energy and repair joints.

Wyatt Okonkwo Wyatt Okonkwo · 7 min read
Research

Ozempic and Wegovy May Help With Chronic Migraine — New Research From the American Academy of Neurology

A new preliminary study found GLP-1 users with chronic migraine had fewer ER visits and less need for migraine medications compared to people taking topiramate.

Wyatt Okonkwo Wyatt Okonkwo · 6 min read
Research

GLP-1 Drugs and Sexual Health: What Doctors Are Seeing (and Not Talking About)

Weight loss from GLP-1 drugs can significantly change hormones, libido, and sexual function — in ways that surprise many patients. Here's what the evidence actually shows.

Tavish Brennan Tavish Brennan · 7 min read
Research

GLP-1 Drugs Are Rewriting the Rules of Cardiovascular Medicine

The SELECT trial marked a watershed moment in cardiology: semaglutide reduced major adverse cardiovascular events by 20% in patients without diabetes, forcing a fundamental rethinking of how we approach heart disease. What began as a diabetes drug has evolved into a cardiovascular therapeutic, challenging decades of assumptions about weight, metabolism, and cardiac risk. This isn't just about adding another tool to the cardiologist's arsenal—it's about recognizing that metabolic health and cardiovascular disease are inseparable, and that addressing one transforms outcomes for the other.

Priya Mehra Priya Mehra · 7 min read
Research

GLP-1 Drugs and Muscle Loss: What the Research Actually Shows

Concerns about muscle loss during GLP-1 treatment have become a flashpoint in metabolic medicine. Patients on semaglutide and tirzepatide report substantial weight loss, but how much is fat versus lean tissue? New studies reveal the composition of that weight loss varies considerably—influenced by protein intake, resistance training, and rate of reduction. Understanding the data helps clinicians and patients optimize outcomes while preserving metabolic health.

Priya Mehra Priya Mehra · 7 min read
Research

Tirzepatide Beats Semaglutide for Weight Loss—But Not for the Heart

The first head-to-head trial shows tirzepatide delivers 5.2 percentage points more weight loss than semaglutide over 72 weeks. But real-world cardiovascular data tells a different story: semaglutide reduced major adverse cardiac events by 57% more than tirzepatide in patients with obesity and cardiovascular disease. The split verdict complicates prescribing decisions.

Brock Halverson Brock Halverson · 6 min read
Research

Novo Nordisk Stock Drops 15% After CagriSema Fails to Beat Zepbound in Head-to-Head Trial — What This Means for GLP-1 Patients

Novo Nordisk's CagriSema missed its primary endpoint in the REDEFINE 4 trial, achieving 20.2% weight loss vs 23.6% for Zepbound. The stock's biggest single-day drop ever raises questions about Novo's GLP-1 pipeline.

Renata Solís Renata Solís · 6 min read
Research

Ozempic for Alzheimer's and Parkinson's? Inside the Emerging Frontier of GLP-1 Brain Research

GLP-1 receptor agonists are being tested for Alzheimer's disease, Parkinson's disease, stroke prevention, and more. Here's what the science actually shows — and what's still unknown.

Brock Halverson Brock Halverson · 8 min read
Research

New Research: Ozempic and Zepbound May Work for Genetic Obesity Too — What the MC4R Study Means

International Journal of Obesity study finds GLP-1 drugs may work for genetic obesity caused by POMC-MC4R pathway deficiency — a population previously considered non-responders.

Wyatt Okonkwo Wyatt Okonkwo · 6 min read
Research

Harvard Scientists: GLP-1 Drugs Like Ozempic Are Just Getting Started — New Uses for Heart Failure, Liver Disease, and More (2026)

Harvard Medical School researchers are discovering GLP-1s treat conditions far beyond obesity — from heart failure to liver disease to substance use disorders.

Dr. Nadine Wulf Dr. Nadine Wulf · 8 min read
Research

WHO Issues First-Ever GLP-1 Drug Guidelines for Obesity — What Cochrane Found About Ozempic, Wegovy, and Zepbound

The World Health Organization has released its first formal guidelines on using GLP-1 medications to treat obesity, backed by three Cochrane systematic reviews. The evidence is strong — but so are the caveats about long-term safety and industry funding.

Brock Halverson Brock Halverson · 8 min read
Research

What Happens When You Stop Ozempic or Wegovy? A Major New Study Has the Answer

A landmark BMJ meta-analysis of 9,341 patients found that weight returns to pre-treatment levels within about 1.7 years of stopping any weight-loss medication — and faster with GLP-1s than behavioral programs. Here's what patients on semaglutide and tirzepatide need to know.

Renata Solís Renata Solís · 8 min read
Research

Roche's New GLP-1/GIP Drug CT-388 Shows 22.5% Weight Loss in Phase II — Phase III Starting Now

Roche just posted Phase II results for CT-388, a new once-weekly GLP-1/GIP dual agonist that matched tirzepatide's performance with up to 22.5% weight loss at 48 weeks. Phase III trials are launching this quarter. Here's what this means for the future of obesity treatment.

Brock Halverson Brock Halverson · 7 min read
Research

Good News for Mounjaro and Zepbound Patients: Tirzepatide May Lower Eye Disease Risk (2026)

A new study published in Ophthalmology suggests that tirzepatide, the active ingredient in Mounjaro and Zepbound, may significantly reduce the risk of diabetic retinopathy — a leading cause of vision loss in adults. This finding adds to the growing body of evidence for GLP-1 benefits beyond weight loss and blood sugar control.

Dr. Nadine Wulf Dr. Nadine Wulf · 7 min read